THE WOODLANDS, TX, Aug.  24, 2026  (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) (&#34;Autonomix&#34; or the &#34;Company&#34;), a medical device company dedicated to advancing precision nerve-targeted

AMIX

Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules

Autonomix Medical secures warrant inducement; near-term cash with dilution risk

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>THE WOODLANDS, TX, Aug.  24, 2026  (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) (&amp;#34;Autonomix&amp;#34; or the &amp;#34;Company&amp;#34;), a medical device company dedicated to advancing precision nerve-targeted</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Autonomix Medical announced a warrant inducement to compel immediate exercise of the July 2026 warrants for 857,462 shares at $5.75, generating roughly $4.9 million in gross proceeds. It also issued unregistered Series E-1 and E-2 warrants (535,913 each) at $6.25, exercisable for five years. The closing is expected by August 26, 2026, with resale registrations to follow, signaling near-term potential dilution but stronger cash runway for development.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Autonomix Medical uses warrant inducement to force immediate July 2026 warrant exercise at $5.75.</li><li>Gross proceeds are expected to be about $4.9 million before fees.</li><li>New Series E-1 and E-2 warrants: $6.25 exercise price; five-year terms.</li><li>Closing of the warrant transaction targeted for around Aug 26, 2026; private placement.</li><li>Maxim Group LLC acted as warrant inducement agent and financial advisor.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Autonomix Medical, Inc. (AMIX)</strong>: Issuer of warrants; financing transaction may dilute existing holders; clinical-stage device company.</li><li><strong>Maxim Group LLC (N/A)</strong>: Warrant inducement agent and financial advisor in the transaction.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The article centers on a financing and equity-structure change via warrant inducement, which directly affects AMIX&#039;s capitalization and near-term liquidity, with potential stock-price implications from dilution and pending registrations.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Warrant exercise date targeted for Aug 26, 2026 may trigger price moves.</li><li>Potential dilution of up to ~1.93 million shares if all warrants are exercised.</li><li>Private placement under the 1933 Act; registration statements filed for resale.</li><li>New warrants at $6.25 could affect future share count and liquidity.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Aggregate July 15, 2026 warrants to be exercised: 857,462 shares at $5.75.</li><li>Gross proceeds expected: approximately $4.9 million before advisory/expenses.</li><li>New Series E-1 and E-2 warrants: 535,913 shares each; exercise price $6.25; five-year term.</li><li>Closing expected on or about Aug 26, 2026; private placement exempt from registration.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term dilution pressure from warrant exercises; cash proceeds modestly improve development funding.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify"><strong>THE WOODLANDS, TX, Aug.  24, 2026  (GLOBE NEWSWIRE) -- </strong>Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/AMIX">AMIX</a>) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor ("Investor") for the immediate exercise of certain outstanding warrants that the Company issued on July 15, 2026 (the "July 2026 Warrants"). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding July 2026 Warrants to purchase an aggregate of 857,462 shares of the Company’s common stock at the exercise price of $5.75. The resale of the shares of common stock issuable upon exercise of the July 2026 Warrants has been registered pursuant to an effective registration statement on Form S-3 (File No. 333-297760). The gross proceeds from the exercise of the warrants are expected to be approximately $4.9 million, prior to deducting financial advisory fees and estimated offering expenses.</p>  <p align="justify">Maxim Group LLC acted as warrant inducement agent and financial advisor in connection with the transaction.</p>  <p align="justify">In consideration for the immediate exercise of the existing warrants in cash, the Company also agreed to issue to the Investor unregistered Series E-1 warrants to purchase an aggregate of 535,913 shares of the Company’s common stock, and unregistered Series E-2 warrants to purchase an aggregate of 535,913 shares of the Company’s common stock (collectively, the "New Warrants"). The New Warrants will each have an exercise price of $6.25 per share, will be exercisable upon issuance, and will expire on the five year anniversary of the date of issuance. The Company has agreed to file a registration statement with the Securities and Exchange Commission ("SEC") covering the resale of the shares of common stock issuable upon exercise of the New Warrants.</p>  <p align="justify">The closing of the warrant exercise transaction is expected to occur on or about August 26, 2026, subject to satisfaction of customary closing conditions.</p>  <p align="justify">The New Warrants described above are being offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the "1933 Act") and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements.</p>  <p align="justify">This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</p>  <p><b>About Autonomix Medical, Inc. </b></p>  <p align="justify">Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.</p>  <p align="justify">We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.</p>  <p>For more information, visit <a href="https://www.globenewswire.com/Tracker?data=ceex3WAJSqhIo1YjI_EnHX9PPtlRarNptElMbeEDenECYOenyMp6XVrok9S1Xp-4Hf4ky_L-MlGkxI6pn0z2EQ==" rel="nofollow" target="_blank">autonomix.com</a> and connect with the Company on <a href="https://www.globenewswire.com/Tracker?data=ZME8BCFZRhSC3M887Iju7xm61bv_rOFpXFbxbxj7y_mgkyk_ftKsy3NHm4Y5vR-CcmhBVdrkjLxbQ3g28yVk2w==" rel="nofollow" target="_blank">X</a>, <a href="https://www.globenewswire.com/Tracker?data=O0rZBiM4COUAFnKexbEnKY8sVWgEU9_FjBBFIt6PowAl_0KKZ8oUmj2It7zJBpbzzlc-c0PeZK7qvXcjBi0J2PNP-P-WJVU-BtFcK8FI4bFJeVxEvSetPLMLmYzRmZc-" rel="nofollow" target="_blank">LinkedIn</a>, <a href="https://www.globenewswire.com/Tracker?data=BoaM5Zdo0vUWayPUIEgJlWDraCspS-chMJ6he90yHnIwAuf3p7iUFmiGNgj_WkNW2rN2EebdtIntMr_YuD4toeTOkb8Sw_RpayaaHsko7dg=" rel="nofollow" target="_blank">Instagram</a> and <a href="https://www.globenewswire.com/Tracker?data=MYBRMsjgz9exaq_KDWpgEAy1wqvFxnVuFg_odyx2va7Mx45dunwRkPw9ETdHIyIR0EZwxsX7g9W_VxOfK5esVXBB9cHLxgKbR-dmWLbJYwKkB23DMqDkftXjWhAzWpte" rel="nofollow" target="_blank">Facebook</a>.</p>  <p align="justify"><b>Forward Looking Statements</b></p>  <p align="justify">Some of the statements in this release are "forward-looking statements," which involve risks and uncertainties. Forward-looking statements include, without limitation, the satisfaction of customary closing conditions related to the warrant transaction and the completion of the warrant transaction. Such forward-looking statements can be identified by the use of words such as "should," "might," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," and "proposes."</p>  <p align="justify">Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, including, but not limited to, the expected completion, timing and size of the warrant transaction, the intended use of proceeds from the transaction and Autonomix’s ability to file a registration statement registering the resale of the securities sold in the transaction. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission ("SEC") on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.</p>  <p align="justify"><b>Investor and Media Contact </b></p>  <p align="justify">JTC Team, LLC<br></br>Jenene Thomas<br></br>908-824-0775<br></br><a href="https://www.globenewswire.com/Tracker?data=ceex3WAJSqhIo1YjI_EnHVC3Wtud7tpqvysj6Xu0TmMJPFvQeBuLv6yzjRgs5jwk3AOcir_N_9tBS7oRfsSXzsjDAVvHfvps5ejQ3t3FAoU=" rel="nofollow" target="_blank">autonomix@jtcir.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgxNTM5MCM3ODAxNTEzIzUwMDExOTk5Mg=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NGRjOWFhYTgtZWVhZS00NTM3LWE3MTUtZmFmMzQ5MjdlODRlLTUwMDExOTk5Mi0yMDI2LTA4LTI1LWVu/tiny/Autonomix-Medical-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/8b0ba1bc-43b1-4445-b895-712da30f7df8"><img src="https://ml.globenewswire.com/media/8b0ba1bc-43b1-4445-b895-712da30f7df8/small/logo-png.png" border="0" width="150" height="87" alt="Primary Logo"></img></a></p>

Autonomix Medical announced a warrant inducement to compel immediate exercise of the July 2026 warrants for 857,462 shares at $5.75, generating roughly $4.9 million in gross proceeds. It also issued unregistered Series E-1 and E-2 warrants (535,913 each) at $6.25, exercisable for five years. The closing is expected by August 26, 2026, with resale registrations to follow, signaling near-term potential dilution but stronger cash runway for development.

News insight

Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules

AI summary

Sentiment rationale

Key facts

Corporate Developments